Compare NNNN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | COLL |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2025 | 2015 |
| Metric | NNNN | COLL |
|---|---|---|
| Price | $33.50 | $45.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.17 |
| AVG Volume (30 Days) | 37.4K | ★ 484.7K |
| Earning Date | 04-28-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.06 | ★ 1.63 |
| Revenue | $6,920,153.00 | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.17 |
| Revenue Next Year | N/A | $3.65 |
| P/E Ratio | $554.67 | ★ $28.05 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $5.18 | $23.23 |
| 52 Week High | $55.65 | $50.79 |
| Indicator | NNNN | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 44.54 |
| Support Level | $32.93 | $45.00 |
| Resistance Level | $43.00 | $49.17 |
| Average True Range (ATR) | 4.09 | 1.97 |
| MACD | 0.00 | -0.31 |
| Stochastic Oscillator | 33.23 | 16.81 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.